Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun
about
Recent advances of novel targeted therapy in non-small cell lung cancerTrials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and FutureNew molecularly targeted therapies for lung cancerAntiangiogenic mechanisms and factors in breast cancer treatmentTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesPredictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft modelsFrom diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert PanelAntitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsTargeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Metastasis: a therapeutic target for cancer.Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.A current review of targeted therapeutics for ovarian cancer.Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach.Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer.VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.Risks and benefits with bevacizumab: evidence and clinical implications.Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongReport of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador.Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.Emerging treatment for advanced lung cancer with EGFR mutation.Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer.A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).Intra-Laboratory Pre-Validation of a Human Cell Based in vitro Angiogenesis Assay for Testing Angiogenesis Modulators.Review of the treatment of metastatic non small cell lung carcinoma: A practical approachThe efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials.Functional CT imaging techniques for the assessment of angiogenesis in lung cancer.
P2860
Q21092930-CF0A52D4-45D0-488F-91F1-0C8E0D62FC2EQ24564024-759BCC3C-06F3-4CE0-AA63-77E0894E17CEQ24680988-F3233F94-C280-4F0E-9DCF-498305B2D388Q26751226-CE8259DF-8785-4EFA-8E76-7AC53EECCAF0Q27014117-33D2B048-D46C-405C-BF3B-72AFCA65B18AQ27302122-0A76CF55-4B49-4B10-8CE1-06C6E678C123Q28066842-D10A0BF9-795B-4FE7-9D60-BBA3034044C2Q28478344-B8A2AA5F-E11E-43B1-AC07-AB9F0DB43BA7Q30358961-E96C8384-30C5-471C-9931-884DE8DE7535Q30439221-CF14A85F-B74B-49DA-87BD-9E6195CC1A29Q33392585-D9255080-D36A-4E81-AD5A-7DFF93D0E59BQ33401450-60A8770E-89AE-4442-B93F-B5E9AB5A4C96Q33436643-734E54A8-B6F6-4786-8E79-06896CBF8C28Q33441143-1B0AA21B-198A-483C-96D9-902FD9DAAD02Q33580998-785B2759-B2A7-484F-BA63-2DC2E63E7D6CQ33622614-2E1E9782-F5C5-498F-8073-D0ADED099D0EQ33728406-76252308-95BB-4277-A18B-7C0BACFA6D50Q33789357-D678C3B8-6715-49B9-89E1-30386B0EC000Q33812240-E0F46AF4-3858-44A0-8016-CB7DD44C574AQ33937644-34950CFD-A659-4FE3-B659-62BE2203752DQ33938441-919EF093-7258-48EB-B2E3-3E7EF9A1E1D0Q33949406-CBEB691C-91AF-48EF-AAB0-909A2B1A00CEQ33972047-A112FACD-78D8-45A7-8899-CC32DD4E3C32Q34039015-41880104-B0A3-4BB0-AE1A-EAB3081F6D87Q34048813-062DB5FB-8AA3-4468-AF88-7E16BB821FA4Q34050239-2E75A4DA-CBC6-43B0-9641-BB9AB8DB2691Q34132643-F7111C49-02D7-463F-8280-6AA13963DF80Q34171922-EC12FE3B-E3B7-41FF-968D-69F7291758D9Q34450520-35923E86-724C-450E-9619-BC8B6D4E889EQ34483953-247933D3-1F4F-4524-BE49-5DB8BADA3403Q34538361-E3C9D556-0097-41F0-9C35-79A5241027EEQ34657570-FCC1CD20-8F33-4459-A4EB-05597E61552EQ34733314-D6F6CB7F-EB4F-4486-967B-64B8DD0296B2Q34806753-7F9C81DE-19E6-4F43-AEA4-FA001EB94418Q34980292-F17B0052-804D-47DD-A5FE-926E7B493522Q35042354-8C1626D5-920A-4482-84FA-288D4C6EBFFBQ35100891-44C0F55A-FE84-408B-AC92-489BB468A3F6Q35113397-AA703C93-0572-4D99-8024-59C3837C9E69Q35173455-F4C38E11-8B6A-4850-8AD7-FEA6486DCC73Q35200388-6207D7ED-3058-4627-9140-D95E88D1C17D
P2860
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Phase I/II trial evaluating th ...... h recurrent non-small-cell lun
@en
Phase I/II trial evaluating th ...... h recurrent non-small-cell lun
@nl
type
label
Phase I/II trial evaluating th ...... h recurrent non-small-cell lun
@en
Phase I/II trial evaluating th ...... h recurrent non-small-cell lun
@nl
prefLabel
Phase I/II trial evaluating th ...... h recurrent non-small-cell lun
@en
Phase I/II trial evaluating th ...... h recurrent non-small-cell lun
@nl
P2093
P921
P356
P1476
Phase I/II trial evaluating th ...... h recurrent non-small-cell lun
@en
P2093
Alan Sandler
David A Eberhard
David A Ramies
David H Johnson
David P Carbone
Diane D Liu
Edward S Kim
Eric Mininberg
P304
P356
10.1200/JCO.2005.02.477
P407
P577
2005-03-07T00:00:00Z